中国β-内酰胺耐药铜绿假单胞菌管理的挑战与策略
本文通过聚焦性叙述性综述,梳理中国β-内酰胺耐药铜绿假单胞菌的流行病学、耐药机制与治疗策略,强调高危克隆传播和碳青霉烯酶多样性,并讨论诊断进展、新型β-内酰胺类药物选择、剂量优化及联合方案。
要点
- 关注中国β-内酰胺耐药铜绿假单胞菌的区域流行趋势和高危克隆传播。
- 碳青霉烯酶流行和多样性是β-内酰胺耐药的重要机制。
- 管理策略包括诊断进展、新型β-内酰胺类药物合理选择、剂量优化和联合方案。
核心结论
- 本文提供理解和管理当代临床实践中β-内酰胺耐药铜绿假单胞菌的结构化框架。
研究设计与样本
- 聚焦性叙述性综述,纳入近期临床、流行病学和机制研究。
主要发现
- 概述了β-内酰胺耐药铜绿假单胞菌当前流行病学,突出区域趋势和高危克隆传播。
- 综述了不断演变的β-内酰胺耐药机制,强调碳青霉烯酶的流行和多样性。
临床怎么用
- 临床管理应结合诊断进展、新型β-内酰胺类药物合理选择、剂量优化和联合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-Lactam antibiotics are the cornerstone of therapy for Pseudomonas aeruginosa infections. Their effectiveness, however, has been increasingly compromised by antimicrobial resistance. This article presents a perspective on the evolving challenges and strategies associated with β-lactam resistance in P. aeruginosa, with a particular focus on China. The perspective was developed through a focused narrative review of recent clinical, epidemiological, and mechanistic studies. We first outline the current epidemiology of β-lactam-resistant P. aeruginosa, highlighting regional trends and the dissemination of high-risk clones. We then review the evolving β-lactam resistance mechanisms, emphasizing the prevalence and variety of carbapenemases. Finally, we discuss therapeutic strategies for managing resistant infections. This includes diagnostic advances, rational selection of novel β-lactam agents, dosing optimization, and combination regimens. Together, these insights provide a structured framework for understanding and managing β-lactam-resistant P. aeruginosa in contemporary clinical practice.
引用
- Li Y, Cai H, Hua X, et al. Challenges and Strategies in Managing β-Lactam-Resistant Pseudomonas aeruginosa in China. J Infect Dis. 2026. PMID: 41824645. doi:10.1093/infdis/jiag033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。